Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2019

View Archived Issues

IP-1867B ablates EGFR inhibitor resistance in adult high-grade gliomas

First-in-human results for the chlamydia vaccine candidate CTH-522

RNA-binding protein 39 degradation inducers patented by the Dana-Farber Cancer Institute

Bristol-Myers Squibb discovers receptor-interacting serine/threonine-protein kinase 1 inhibitors

LDD-1819 has cell reprograming and dual kinase inhibitory activity

New chemical entities designed by DINGOS machine learning model

Phase II biomarker study of oral dexpramipexole in moderate to severe eosinophilic asthma

Positive recommendation to continue enrollment in phase Ib study of OTS Allocetra

Vanda receives complete response letter regarding sNDA for Hetlioz for treatment of jet lag disorder

Preclinical data presented for the novel re-engineered lupus autoantibody PAT-DX1

SU-011 improves glycemic control in vivo without the risk of hypoglycemia and weight gain

Exelixis discovers AXL/Mer/c-Met inhibitors

RAPT Therapeutics describes new C-C chemokine receptor type 4 antagonists

PD-1/PD-L1 interaction inhibitors patented by Bristol-Myers Squibb

Sarepta Therapeutics receives complete response letter for golodirsen

Cephamycins treat spore-forming bacteria, prevent relapses

FDA approves Xenleta for the treatment of community-acquired bacteria pneumonia

Oxurion reports topline results from phase IIa study of THR-317 plus ranibizumab in DME

Farxiga meets primary endpoint in landmark phase III DAPA-HF study

First patient enrolled in phase IIb study of ABX-464 in patients with ulcerative colitis

Forendo Pharma initiates dosing in phase Ib study of FOR-6219

What wakes up CMV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...